Tag: paclitaxel

CIRSE

CIRSE updates position on paclitaxel use in peripheral arteries

The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has released a statement on the use of paclitaxel-coated balloons and stents in the treatment...

Update from the SVS paclitaxel safety task force

In response to the updated letter to healthcare providers from the US Food and Drug Administration (FDA), the Society for Vascular Surgery (SVS) released...

UK MHRA forms Expert Advisory Group to review paclitaxel devices while...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the Food and Drug Administration (FDA) in the USA have both recently...
pooled

Pooled analysis of four RCTs finds no increased mortality with paclitaxel-coated...

A new paper looking specifically at mortality has found no difference in deaths between paclitaxel-coated balloons and uncoated balloons when used in the femoropopliteal...

Sirolimus has “a much wider” safety window and shows fewer local...

 Paclitaxel kills the cells in the artery wall; sirolimus simply stuns them. So says Peter Gaines (Sheffield, UK) at VLF 2019 while commenting on...
paclitaxel

Paclitaxel-releasing devices: An unfolding story

Paclitaxel Timeline: Meta-analysis finds a higher risk of death in the long term when paclitaxel-coated devices are used in the leg Without additional long-term...
FDA

US FDA continues to investigate paclitaxel devices in the leg

A meta-analysis published in the Journal of the American Heart Association (JAHA) late last year by Konstantinos Katsanos (Patras, Greece) and colleagues, suggesting an...

“No evidence of increased long-term mortality” with paclitaxel-eluting stent in new...

“Drug-eluting stents (DES) are important additions to the armamentarium of devices used for peripheral artery revascularization, associated with decreased rates of restenosis and target...

Vascular Leaders Forum discussions seek consensus on paclitaxel

The Vascular Leaders Forum (VLF, 1–2 March, Washington DC, USA), hosted by the non-profit organisation VIVA Physicians, is a special consortium which was called...
Medtronic

Two companies with paclitaxel-coated devices issue corrections to published data

Both Medtronic and Cook Medical have issued corrections to published data regarding the safety of their paclitaxel-coated devices. While Medtronic have revised IN-PACT post-market...
occlusion

Novel catheter delivering liquid paclitaxel safely and effectively prevents restenosis in...

The efficacy and safety of a novel catheter delivering liquid paclitaxel for the prevention of restenosis in below-the-knee lesions has been confirmed by study...
Medtronic

Medtronic revises IN.PACT post-market study data due to programming error, but...

Medtronic has issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the clinical data reporting isolated...

Passeo-18 Lux DCB remains safe and effective at two years with...

Two-year data on the Passeo-18 Lux drug-coated balloon (DCB; Biotronik) continue to validate its safety and effectiveness in intra-inguinal arteries. Gunnar Tepe from the...

New analysis finds “an association of survival” with drug-coated device use...

A recent US-wide, multicentre analysis has found no evidence of increased all-cause mortality associated with the use of paclitaxel-coated devices compared with non-drug-coated devices...

New data release at LINC 2019 reinforces safety profile of low-dose...

 Sean Lyden (Cleveland, USA) and Fabrizio Fanelli (Rome, Italy) discuss the safety and future of drug-coated balloons (DCB) in light of the latest pooled...

Patient-level analysis shows no correlation between paclitaxel and mortality—reactions from LINC

 Renowned experts expressed confidence in the continued use of paclitaxel-coated devices after independent patient-level data presented at LINC 2019 did not show correlation between...
paclitaxel

ISET Paclitaxel Town Hall: Vast majority of attendees will not change...

The discussion around the use of paclitaxel-coated and eluting devices continues at the 31st International Symposium on Endovascular Therapy (ISET; 27-30 January 2019, Hollywood,...
SCAI

Society for Cardiovascular Angiography and Interventions supports continued use of paclitaxel...

Experts from the Society for Cardiovascular Angiography and Interventions (SCAI) have reviewed the recent meta-analysis by Katsanos and colleagues and have concluded that the...
stellarex

Latest data from Philips reinforces the safety profile of Stellarex low-dose...

A new pooled analysis of patient-level data from Philips demonstrates the “strong safety profile” of the its Stellarex drug-coated balloon (DCB) in above-the-knee studies,...

IN.PACT independent patient-level meta-analysis shows no correlation between paclitaxel exposure and...

 A renowned panel, moderated by Dierk Scheinert (Leipzig, Germany), comprising Peter Schneider (Honolulu, USA), John Laird (St Helena, USA) and Thomas Zeller (Bad Krozingen,...
BIBLIOS

BIBLIOS trial has obtained ethics approval and initiated patient enrolment

The BIBLIOS trial has received Ethics Committee (EC) approval, and enrolled its first patient. This announcement comes from Wouter Lansink, who will be treating this...
Medtronic

Patient-level survival analysis demonstrates no link between paclitaxel dose and mortality...

New data on the IN.PACT Admiral drug-coated balloon (DCB; Medtronic) in patients with peripheral arterial disease (PAD) in the superficial femoral (SFA) and popliteal...

Data presented at LINC confirm the safety and effectiveness of Zilver...

Findings presented at the Leipzig Interventional Course (LINC; 22–25 January 2019, Leipzig, Germany) contradict the results of a meta-analysis published in the Journal of...

US FDA evaluating paclitaxel data, recommend patient surveillance

The impact of the 2018 meta-analysis of randomised paclitaxel-device trials, published in the Journal of the American Heart Association by Konstantinos Katsanos et al,...
medtronic

Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical...

Speaking to investors at the JP Morgan healthcare conference in San Francisco, executives from Medtronic and Boston Scientific said their data do not show...

Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Medtronic has issued the following statement regarding revised clinical study data: On 15 February, 2019, Medtronic issued a statement regarding a programming error in the...

SWEDEPAD 1 and SWEDEPAD 2 trials halt inclusion after Katsanos et...

Interventional News has learned that inclusion into the SWEDEPAD studies, that are examining benefits of drug-eluting technology for peripheral arterial disease patients, has been...

Meta-analysis finds a higher risk of death in the long term...

 Konstantinos Katsanos (Patras, Greece) tells Interventional News about new data from a meta-analysis that has been published in the Journal of the American Heart...
medtronic

Meta-analysis finds a higher risk of death in the long term...

New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...

Paclitaxel-eluting stent loses BATTLE against bare metal stent

The BATTLE trial comparing a drug-eluting stent (Zilver PTX, Cook Medical) vs. a bare metal stent (Misago, Terumo) for the treatment of intermediate femoropopliteal...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...